Study Description
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu)
vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer
(OMPC) progressing after definitive therapy to their primary tumor. The data generated
from this study will provide evidence for the treatment of AAA617 in early-stage prostate
cancer patients to control recurrent tumor from progressing to fatal metastatic disease
while preserving quality of life by delaying treatment with androgen deprivation therapy
(ADT). All participants will be assessed for eligibility and will undergo baseline disease
assessments including a mandatory gallium (68Ga) gozetotide (also known as
[68Ga]Ga-PSMA-11) or piflufolastat (18F) ( also known as[18F]DCFPyL) PET/CT scan and
conventional imaging (i.e., CT/MRI and bone scans).
Piflufolastat (18F) PET/CT scan will be performed in countries where it is approved.
Stereotactic Body Radiation Therapy (SBRT) will be administered to all metastatic
Prostate Cancer (PC) lesions after randomization and before the start of treatment with
AAA617 or observation.
- The duration of SBRT procedures is approximately 3 weeks.
- For participants randomized to the investigational arm (AAA617), the treatment
duration will be up to 4 cycles of AAA617. For participants randomized to the
control arm (observation) the treatment duration will end at the last fraction of
SBRT administration.
- The visit frequency will be every week 1 and 3 of each of the 4 cycles and every 16
weeks thereafter (for both arms) until first event of disease progression (RECIST
1.1)
- The study duration is approximately 6.5 years.
Interventions
AAA617
Eligibility Criteria
Key Inclusion criteria:
1. Histologically confirmed prostate cancer prior to randomization
2. Participants must have biochemically recurrent disease after definitive treatment to
prostate by Radical Prostatectomy ((RP), (alone or with post-operative radiation to
prostate bed/pelvic nodes)) or External beam Radiation Therapy (XRT), (prostate
alone or prostate with seminal vesicle and/or pelvic nodes) and/or brachytherapy
prior to randomization. Biochemical recurrence is defined as: nadir PSA + 2 ng/mL
post XRT (if participant received-radiation therapy to intact prostate) and PSA >
0.2 ng/mL and rising post RP (with or without post-operation Radiation Therapy (RT))
3. Participants must have OMPC with =< 5 PSMA-positive metastatic lesions on screening
PSMA PET/CT scan (with either gallium (68Ga) gozetotide or piflufolastat (18F)) as
visually assessed by BIRC based on the methodology proposed in the Prostate Cancer
Molecular Imaging Standardized Evaluation (PROMISE v2) (Seifert et al 2023); for
further details, please refer to Section 8.1 and the Imaging Manual. Metastatic
lesions may include regional/pelvic lymph nodes (N1), distant lymph nodes (M1a),
bone (M1b), lung and others visceral (M1c) except liver and brain classified using
AJCC 8. When counting the number of oligometastatic lesions, each lesion is counted
as distinct metastasis irrespective of its anatomical location (e.g., one pelvic and
one extra-pelvic lymph node will be counted as two metastatic lesions)
4. At least 1 PSMA-positive lesion should be a distant metastasis (M1) per AJCC8
classification at screening. For AJCC M staging, PSMA PET information should be used
5. Participants must have a negative conventional imaging for M1 disease at screening.
Note:
- For a participant not to be eligible, CI positive M1 lesions should be
unequivocal in CI scans, i.e., potentially not attributable to findings thought
to represent something other than tumor (e.g., degenerative, or post-traumatic
changes or Paget's disease in bone lesions). For conventional imaging
assessments, bone lesions must be assessed by bone scan only and soft tissue
lesions must be assessed by CT/MRI scans only at screening.
- Prior knowledge of PSMA PET positivity should not influence the radiologist
(reader) in determination of CI positivity. Two different readers will be
involved, one reader for PSMA PET scan and one reader for CI: Reader will be
blinded to PSMA PET scan results while reading CI scans. Reader should not
modify their assessment of CI scans (e.g. changing a lesion previously
identified as equivocal in CI to unequivocal) after reading the PSMA PET scan.
Similarly, biopsy positivity should not influence the reader in the assessment
of CI positivity. More details on the reading paradigm will be provided in the
imaging charter
- MRI for radiation treatment planning may show M1 disease but this will not
exclude the participant from the study if the lesion is deemed negative per
baseline CT or bone scans
- Participants with pelvic disease (N1) seen in conventional imaging are allowed
if the local spread is below common iliac bifurcation (per AJCC 8 definition of
local disease)
- Distant lymph node disease (M1a) that is visible per CI and less than 10mm in
the short axis is not exclusionary irrespective of PSMA PET positivity.
- If a previously surgically removed lesion was unequivocal for M1 by bone scan
or CT, the participant is not eligible.
6. All metastatic lesions detected at screening should be amenable to SBRT
7. Non-castration testosterone level >100 ng/dL at screening
Key Exclusion criteria:
1. Participants with de novo OMPC at screening
2. Unmanageable concurrent bladder outflow obstruction or urinary incontinence at
screening. Note: participants with bladder outflow obstruction or urinary
incontinence, which is manageable and controlled with best available standard of
care (incl. pads, drainage) are allowed
3. Prior therapy with:
1. ADT including bilateral orchiectomy
- Participants who had XRT or RP and completed adjuvant ADT (or ADT+ARPI)
prior to recurrence are eligible to participate if the last dose of ADT
(or ADT+ARPI) was before 12 months from randomization. Participants who
had prior SBRT with short term ADT (3-6 months) are also allowed if the
ADT was stopped at least 12 months before randomization.
- Participants who discontinued ADT due to disease progression are not
allowed (i.e., Castration-Resistant Prostate Cancer (CRPC) participants)
2. Other hormonal therapy. e.g.,
- Use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride),
other steroidogenesis inhibitors (aminoglutethimide) if used in the
context of prostate cancer treatment. Same medications are allowed if used
for other indications: e.g., Benign Prostatic Hyperplasia (BPH), if
stopped at least 5 half-lives before randomization.
- First-generation anti-androgens (bicalutamide, flutamide, nilutamide,
cyproterone)
- Second generation anti-androgens (e.g., enzalutamide, apalutamide and
darolutamide)
- CYP17 inhibitors (e.g., abiraterone acetate, orteronel, galeterone,
ketoconazole). Short term ketoconazole treatment (<28 days) is permitted
3. Radiopharmaceutical agents (e.g., Strontium-89, PSMA-targeted radioligand
therapy)
4. Immunotherapy (e.g., sipuleucel-T)
5. Chemotherapy, except if administered in the adjuvant/neoadjuvant setting
completed > 12 months before randomization
6. Any other investigational or systemic agents for metastatic disease
4. Radiation therapy external beam radiation therapy (EBRT) and brachytherapy within 28
days before randomization
5. Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, hormonal
therapy (see ADT initiation guidance in Section 6.8.2), Poly Adenosine
Diphosphate-Ribose Polymerase (PARP) inhibitor, biological therapy or
investigational therapy
6. Diagnosed at screening with other malignancies that are expected to alter life
expectancy or may interfere with disease assessment. However, participants with a
prior history of malignancy that has been adequately treated and who have been
disease/treatment free for more than 3 years are eligible, as are participants with
adequately treated non-melanoma skin cancer and superficial bladder cancer.
7. History or current diagnosis of ECG abnormalities indicating significant risk of
safety for participants participating in the study such as:
- Concomitant clinically significant cardiac arrhythmias, e.g. sustained
ventricular tachycardia, and clinically significant second or third degree
Atrioventricular (AV) block without a pacemaker
- History of familial long QT syndrome or known family history of Torsades de
Pointe
8. Participants in immediate need of ADT as assessed by the investigator.
Other protocol defined Inclusion/Exclusion may apply.
Novartis Investigative Site
Recruiting
Adelaide,South Australia,5000,Australia
Novartis Investigative Site
Recruiting
Malvern,Victoria,3144,Australia
Novartis Investigative Site
Recruiting
Darlinghurst,New South Wales,2010,Australia
Novartis Investigative Site
Recruiting
Wien,1090,Austria
Novartis Investigative Site
Recruiting
Gent,9000,Belgium
Novartis Investigative Site
Recruiting
Wilrijk,2610,Belgium
Novartis Investigative Site
Recruiting
Montreal,Quebec,H3t 1e2,Canada
Novartis Investigative Site
Recruiting
Quebec,G1j 1z4,Canada
Novartis Investigative Site
Recruiting
Montreal,Quebec,H2x 1r9,Canada
Novartis Investigative Site
Recruiting
Olomouc,CZE,779 00,Czechia
Novartis Investigative Site
Recruiting
Ostrava,Poruba,708 52,Czechia
Novartis Investigative Site
Recruiting
Praha 5,150 06,Czechia
Novartis Investigative Site
Recruiting
Bron,69677,France
Novartis Investigative Site
Recruiting
Clermont-Ferrand,63011,France
Novartis Investigative Site
Recruiting
Rouen,76038,France
Novartis Investigative Site
Recruiting
Saint Herblain,44805,France
Novartis Investigative Site
Recruiting
Saint-Cloud,Hauts De Seine,92210,France
Novartis Investigative Site
Recruiting
Bordeaux,33076,France
Novartis Investigative Site
Recruiting
Debrecen,4032,Hungary
Novartis Investigative Site
Recruiting
Haifa,3109601,Israel
Novartis Investigative Site
Recruiting
Jerusalem,9112001,Israel
Novartis Investigative Site
Recruiting
Petach Tikva,4941492,Israel
Novartis Investigative Site
Recruiting
Tel Aviv,6423906,Israel
Novartis Investigative Site
Recruiting
Beer Sheva,8457108,Israel
Novartis Investigative Site
Recruiting
Milano,MI,20141,Italy
Novartis Investigative Site
Recruiting
Fukuoka city,Fukuoka,812-8582,Japan
Novartis Investigative Site
Recruiting
Fukuoka,812-0033,Japan
Novartis Investigative Site
Recruiting
Fukushima city,Fukushima,960 1295,Japan
Novartis Investigative Site
Recruiting
Kyoto,606 8507,Japan
Novartis Investigative Site
Recruiting
Sapporo city,Hokkaido,060 8648,Japan
Novartis Investigative Site
Recruiting
Kobe,Hyogo,650-0047,Japan
Novartis Investigative Site
Recruiting
Kanazawa,Ishikawa,920 8641,Japan
Novartis Investigative Site
Recruiting
Yokohama-city,Kanagawa,236-0004,Japan
Novartis Investigative Site
Recruiting
Kashiwa,Chiba,277 8577,Japan
Novartis Investigative Site
Recruiting
Fukuoka,811-0213,Japan
Novartis Investigative Site
Recruiting
Singapore,119228,Singapore
Novartis Investigative Site
Recruiting
Singapore,168583,Singapore
Novartis Investigative Site
Recruiting
Bratislava,Slovak Republic,83310,Slovakia
Novartis Investigative Site
Recruiting
Kosice,041 91,Slovakia
Novartis Investigative Site
Recruiting
Granada,Andalucia,18014,Spain
Novartis Investigative Site
Recruiting
Sevilla,Andalucia,41013,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08036,Spain
Novartis Investigative Site
Recruiting
Madrid,28041,Spain
Novartis Investigative Site
Recruiting
Valencia,Comunidad Valenciana,46010,Spain
Novartis Investigative Site
Recruiting
El Palmar,Murcia,30120,Spain
Novartis Investigative Site
Recruiting
Madrid,28040,Spain
Novartis Investigative Site
Recruiting
Geneve 14,1211,Switzerland
Novartis Investigative Site
Recruiting
Luzern,6006,Switzerland
Novartis Investigative Site
Recruiting
Taipei,11217,Taiwan
Novartis Investigative Site
Recruiting
Taoyuan,33305,Taiwan
Novartis Investigative Site
Recruiting
Taipei,103616,Taiwan
Cancer Specialists of North Florida
Recruiting
Jacksonville,Florida,32256,United States
Richard Cassidy
Ryan Veldhuizen
BAMF Health
Recruiting
Grand Rapids,Michigan,49503,United States
Brandon Mancini
Jennifer Hoseth
Johns Hopkins Kimmel Com Cancer Ctr
Recruiting
Baltimore,Maryland,21231,United States
Ana Kiess
Oregon Urology Institute
Recruiting
Springfield,Oregon,97477,United States
Bryan Mehlhaff
Profound Research LLC
Recruiting
Royal Oak,Michigan,48073,United States
Adam Gadzinski
Catherine Maples
Highlands Oncology Group
Recruiting
Fayetteville,Arkansas,72703,United States
Joseph Thaddeus Beck
Wash U School of Medicine
Recruiting
Saint Louis,Missouri,63110,United States
Ellen Haennie
Hiram Gay
Carolina Urologic Research Center, LLC
Recruiting
Myrtle Beach,South Carolina,29572,United States
Neal D Shore
Mayo Clinic Rochester
Recruiting
Rochester,Minnesota,55905,United States
Ryan Phillips
Rocky Mountain Cancer Centers
Recruiting
Longmont,Colorado,80501,United States
Allen Cohn
Virginia Oncology Associates
Recruiting
Norfolk,Virginia,23502,United States
Mark Fleming
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.